Myriad Genetics’ Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can identify which men with intermediate or high-risk prostate cancer will benefit from combining androgen deprivation therapy (ADT) with standard therapy, a study shows. The data, “Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer,” were presented in a poster session at the 2020 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium, held recently in San Francisco. “While it has been demonstrated that multi-modality therapy [combination therapy] can improve overall survival in prostate cancer, it comes at the risk of increased morbidity and increased cost to the healthcare system,” Jonathan Tward, MD, PhD, the study’s first author and associate professor in the department of radiation oncology at the University of Utah, said in a press release. “Prolaris provides a unique tool that can accurately predict which patients with high-risk prostate cancer will truly benefit from multi-modality therapy and conversely which patients with lower risk can safely avoid such treatments,” Tward said. The test analyzes the activity of 46 genes involved in cancer cell proliferation and determines their aggressiveness, using tissue collected during a biopsy to confirm a cancer diagnosis. Clinicians can use the test to better predict the prognosis of prostate cancer over 10 years. It works in combination with a person’s Gleason score — a measure of prostate cancer aggressiveness based on how cells look under a microscope — and levels of prostate cancer antigen (PSA), a biomarker of prostate cancer.